Skip to main content

Table 4 The Comparison of serological CMV markers in Groups

From: Antiviral therapy in neonatal cholestatic cytomegalovirus hepatitis

Groups   CMV IgM (+) patient
no/total
CMV IgG avidity >0,8 patient
n
* ΨCMV DNA
copy/ml
Group 1 (n = 7) Initial 7/7 5 2230(166–9240)
  Posttreatment 0/7 3 14 (8–1930)
Group 2 (n = 5) Initial 3/5 3 2178(158–2917)
  Control 3/5 1 1915(656–2900)
  1. The ratio of patients, in each group, having affirmative results in the second evaluation (p < 0.01)
  2. * Median (minimum-maximum)
  3. Ψ The comparison of value changes between first and second evaluation (p < 0.05)